版本:
中国

BRIEF-Karyopharm doses first patient in pivotal phase 3 boston study

June 7 Karyopharm Therapeutics Inc:

* Karyopharm doses first patient in pivotal phase 3 boston study evaluating selinexor in patients with relapsed/refractory multiple myeloma

* Karyopharm-Expects to include over 100 clinical sites internationally in boston study, to complete enrollment in 2018, with top-line data anticipated in 2019

* Karyopharm therapeutics inc- intend to use boston study data to support an nda filing for selinexor for treatment of relapsed or refractory myeloma Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐